As the supplier of the body’s blood, the heart must also supply its own blood to keep itself nourished and oxygenated. The heart’s blood supply comes from the coronary arteries, which receive oxygenated blood from the pulmonary veins. Normally, the heart receives enough oxygenated blood, but with chronic thromboembolic pulmonary hypertension (CTEPH)…
Search results for:
A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found. “NDRG1 and related key gene axes may serve as potential therapeutic targets for CTEPH,” researchers wrote. The study, “Single-cell transcriptomics…
Bayer is presenting six abstracts on studies investigating riociguat for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) at the 2016 American Thoracic Society (ATS) International Conference now taking place in San Francisco, California. Riociguat (BAY 63-2521, trade name Adempas) is a stimulator of soluble guanylate cyclase (sGC). It is indicated for the treatment…
Social Clips
Searching For Information On CTEPH?
Searching for information on #CTEPH? Read the most relevant articles here: https://bit.ly/1Mdo9fV…
This podcast series, created and produced by phaware, is being offered as a regular guest feature on Pulmonary Hypertension News to bring the voices and life experiences of PH patients, family members, caregivers, healthcare specialists, and others to our readers. You may listen to the podcast directly, or read it…
Actelion Pharmaceuticals has withdrawn all ongoing worldwide requests for expanded approval of Opsumit (macitentan), a pulmonary arterial hypertension (PAH) medicine, to treat adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The decision was not driven by any safety concerns, Actelion, one of …
Researchers at Leiden University Medical Center in The Netherlands recently published in the journal Diagnostic and Interventional Radiology a review on the value of computed tomography (CT) as a diagnostic tool for pulmonary embolism. The study is entitled “The role of computed tomography…
News
Study: Robot-assisted Surgery Lowers Heart Strain, Improves Exercise Capacity in CTEPH Patients
Robot-assisted pulmonary artery denervation (PADN) — a minimally invasive surgical procedure that destroys some of the nerves innervating the pulmonary artery to reduce blood pressure — can lower heart strain and improve exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH). That finding was reported in…
Bayer has opened its second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a grant funding program to support clinical research projects into pulmonary hypertension (PH), particularly those focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The program, one of…
Some of the most difficult-to-treat patients with pulmonary hypertension are those with chronic thromboembolic pulmonary hypertension (CTEPH). These patients are in the most severe category of pulmonary hypertension: World Health Organization (WHO) Group 4. CTEPH patients have curative potential if they have no resectable lesions or contraindications…
Actelion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA) specifying that the company needs to conduct further studies and obtain more data in order to accurately assess the use of Opsumit (macitentan) in the treatment of patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The…
Patricia Middings of Chester, N.J., is the winner of “Breathless Moments,” a photo contest launched by Bayer in order to raise awareness for chronic thromboembolic pulmonary hypertension (CTEPH). The idea of the challenge was to portray inspirational moments, events or sights that leave someone breathless. Contest judges Trace Cluck,…